Market Overview:
The global multiple sclerosis drugs market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of multiple sclerosis, rising awareness about available treatment options, and technological advancements in the field of MS drugs. The global multiple sclerosis drugs market is segmented on the basis of type into injectable medications, oral medications, and others. In terms of application, the market is segmented into adults and children. Geographically, the global MS drugs market is segmented into North America, Latin America, Europe Asia Pacific and Middle East & Africa.
Product Definition:
Multiple sclerosis drugs are used to help relieve the symptoms of multiple sclerosis. They work by reducing inflammation and preventing damage to the nerves.
Injectable Medications:
Injectable medications are drugs that are given into the body by injection. They can be administered every 3 to 4 weeks and have a more prolonged effect than oral medications. The most commonly used injectable is insulin, which is used in diabetes treatment; however, there are many others such as growth hormone (GH), interferon, long-acting local anesthetics like Lidocaine Hydrochloride (LH), and various vaccines among others.
Oral Medications:
Oral medications are drugs that are taken by mouth. They may be in tablet or capsule form and can be administered as a single dose or in divided doses throughout the day as required. The most common types of oral medications include anti-epileptics, analgesics (painkillers), antihypertensives, antibiotics, antidiabetics and antidepressants among others.
Application Insights:
The adults segment held the largest share of more than 60.0% in 2017. The growing geriatric population is one of the major drivers for this segment growth as a high proportion of multiple sclerosis patients are diagnosed in the adult population (above 40 years). According to data published by WHO, it has been estimated that nearly 10 million people aged 50 or above were registered globally in 2016 and this number is expected to reach 22 million by 2050, thus presenting a lucrative opportunity for market players during the forecast period.
Moreover, increasing awareness about MSS among healthcare providers and neurologists is also expected to contribute significantly towards market growth over the forecast period.
Regional Analysis:
North America dominated the global multiple sclerosis drugs market in 2017. This can be attributed to the presence of key players, high disease prevalence, and availability of novel therapies. In addition, higher healthcare expenditure and a well-developed reimbursement structure are some other factors contributing to its largest share. The region is expected to maintain its position during the forecast period due to ongoing clinical trials for new drug molecules as well as existing drugs undergoing modification in their dosage forms or combination products.
Asia Pacific is estimated to witness lucrative growth over the coming years owing rising awareness about multiple sclerosis among people coupled with increasing disposable income resulting in an improved standard of living which ultimately leads towards better treatment outcomes for patients suffering from this condition thus positively influencing overall revenue generation from 2018 till 2030 time frame.
Growth Factors:
- Increasing incidence of multiple sclerosis (MS) across the globe
- Growing awareness about MS and its treatment options
- Rising demand for novel and effective MS drugs
- Technological advancements in the field of MS drugs development
- increasing healthcare expenditure by governments and private players
Scope Of The Report
Report Attributes
Report Details
Report Title
Multiple Sclerosis Drugs Market Research Report
By Type
Injectable Medications, Oral Medications, Others
By Application
Adults, Children
By Companies
Biogen, Sanofi, Novartis, Teva, Merck KGaA, Bayer, ACORDA, Mallinckrodt
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
212
Number of Tables & Figures
149
Customization Available
Yes, the report can be customized as per your need.
Global Multiple Sclerosis Drugs Market Report Segments:
The global Multiple Sclerosis Drugs market is segmented on the basis of:
Types
Injectable Medications, Oral Medications, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Adults, Children
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Biogen
- Sanofi
- Novartis
- Teva
- Merck KGaA
- Bayer
- ACORDA
- Mallinckrodt
Highlights of The Multiple Sclerosis Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Injectable Medications
- Oral Medications
- Others
- By Application:
- Adults
- Children
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Multiple Sclerosis Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Multiple sclerosis drugs are medications used to treat multiple sclerosis. They can help reduce the number and severity of symptoms, including paralysis, blindness, and seizures.
Some of the key players operating in the multiple sclerosis drugs market are Biogen, Sanofi, Novartis, Teva, Merck KGaA, Bayer, ACORDA, Mallinckrodt.
The multiple sclerosis drugs market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Multiple Sclerosis Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Multiple Sclerosis Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Multiple Sclerosis Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Multiple Sclerosis Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Multiple Sclerosis Drugs Market Size & Forecast, 2018-2028
4.5.1 Multiple Sclerosis Drugs Market Size and Y-o-Y Growth
4.5.2 Multiple Sclerosis Drugs Market Absolute $ Opportunity
Chapter 5 Global Multiple Sclerosis Drugs Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Multiple Sclerosis Drugs Market Size Forecast by Type
5.2.1 Injectable Medications
5.2.2 Oral Medications
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Multiple Sclerosis Drugs Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Multiple Sclerosis Drugs Market Size Forecast by Applications
6.2.1 Adults
6.2.2 Children
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Multiple Sclerosis Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Multiple Sclerosis Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Multiple Sclerosis Drugs Analysis and Forecast
9.1 Introduction
9.2 North America Multiple Sclerosis Drugs Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Multiple Sclerosis Drugs Market Size Forecast by Type
9.6.1 Injectable Medications
9.6.2 Oral Medications
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Multiple Sclerosis Drugs Market Size Forecast by Applications
9.10.1 Adults
9.10.2 Children
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Multiple Sclerosis Drugs Analysis and Forecast
10.1 Introduction
10.2 Europe Multiple Sclerosis Drugs Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Multiple Sclerosis Drugs Market Size Forecast by Type
10.6.1 Injectable Medications
10.6.2 Oral Medications
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Multiple Sclerosis Drugs Market Size Forecast by Applications
10.10.1 Adults
10.10.2 Children
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Multiple Sclerosis Drugs Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Multiple Sclerosis Drugs Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Multiple Sclerosis Drugs Market Size Forecast by Type
11.6.1 Injectable Medications
11.6.2 Oral Medications
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Multiple Sclerosis Drugs Market Size Forecast by Applications
11.10.1 Adults
11.10.2 Children
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Multiple Sclerosis Drugs Analysis and Forecast
12.1 Introduction
12.2 Latin America Multiple Sclerosis Drugs Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Multiple Sclerosis Drugs Market Size Forecast by Type
12.6.1 Injectable Medications
12.6.2 Oral Medications
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Multiple Sclerosis Drugs Market Size Forecast by Applications
12.10.1 Adults
12.10.2 Children
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Multiple Sclerosis Drugs Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Multiple Sclerosis Drugs Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Multiple Sclerosis Drugs Market Size Forecast by Type
13.6.1 Injectable Medications
13.6.2 Oral Medications
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Multiple Sclerosis Drugs Market Size Forecast by Applications
13.10.1 Adults
13.10.2 Children
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Multiple Sclerosis Drugs Market: Competitive Dashboard
14.2 Global Multiple Sclerosis Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Biogen
14.3.2 Sanofi
14.3.3 Novartis
14.3.4 Teva
14.3.5 Merck KGaA
14.3.6 Bayer
14.3.7 ACORDA
14.3.8 Mallinckrodt
